Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833073 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
A Phase 2 study of Urinary Bladder Neoplasms and Non-Muscle Invasive Bladder Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06833073 is a Phase 2 study of Urinary Bladder Neoplasms and Non-Muscle Invasive Bladder Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 308 participants, roughly in line with the 297-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT06833073, a Phase 2 study of Urinary Bladder Neoplasms and Non-Muscle Invasive Bladder Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.
Conditions Studied
Interventions
- BIOLOGICAL Intismeran autogene
- BIOLOGICAL BCG
Study Locations (20)
California
- Michael G Oefelein Clinical Trials ( Site 0138) - Bakersfield
- Genesis Research, LLC ( Site 0141) - Los Alamitos
- USC Norris Comprehensive Cancer Center ( Site 0123) - Los Angeles
- Genesis Healthcare-Torrance ( Site 0140) - Torrance
- Genesis Research LLC ( Site 0118) - Torrance
Texas
- Texas Oncology-Austin Central ( Site 0107) - Austin
- Urology Austin, PLLC ( Site 0109) - Austin
Colorado
- Urology Associates ( Site 0144) - Littleton
Florida
- Urological Research Network ( Site 0133) - Hialeah
Illinois
- Associated Urological Specialists - Chicago Ridge ( Site 0139) - Chicago Ridge
Louisiana
- Southern Urology, LLC ( Site 0145) - Lafayette
Missouri
- University of Missouri Health Care ( Site 0126) - Columbia
Nebraska
- NHO Revive Research Institute, LLC ( Site 0137) - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2031-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06833073
The ClinicalTrials.gov registry entry for NCT06833073 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 297-participant average among 19 other Urinary Bladder Neoplasms trials with a reported enrollment target. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Urinary Bladder Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Intismeran autogene is the first listed.
NCT06833073 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT06833073 about?
NCT06833073 is a clinical study titled "A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)". Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of ge...
What is the current status of trial NCT06833073?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2025-03-11. Estimated completion is 2031-09-03.
What conditions does trial NCT06833073 study?
This clinical trial studies the following conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ.
What interventions are being tested in trial NCT06833073?
The interventions under investigation include: Intismeran autogene (BIOLOGICAL), BCG (BIOLOGICAL).
Who is sponsoring clinical trial NCT06833073?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833073 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
ACTIVE NOT RECRUITING · Phase 2
-
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
COMPLETED · Phase 2
-
Cabozantinib for Advanced Urothelial Cancer
COMPLETED · Phase 2
-
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
COMPLETED · Phase 2
Explore more on PlainTrial
Urinary Bladder Neoplasms
All registered trials for this condition
Non-Muscle Invasive Bladder Neoplasms
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.